The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

[1]  Xiang Liu,et al.  Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians , 2013, The Pharmacogenomics Journal.

[2]  Geoffrey Liu,et al.  Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians , 2013, PloS one.

[3]  M. Nalls,et al.  Genome-Wide Association Study of Retinopathy in Individuals without Diabetes , 2013, PloS one.

[4]  R. Mckinnon,et al.  Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. , 2012, Pharmacogenomics.

[5]  Pierre Michel,et al.  Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. , 2011, The Lancet. Oncology.

[6]  S. Gruber,et al.  Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients , 2011, Cancer.

[7]  M. Baiget,et al.  A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer , 2011, British Journal of Cancer.

[8]  S. Saxena,et al.  If You Could Only Choose Five Psychotropic Medicines: Updating the Interagency Emergency Health Kit , 2011, PLoS medicine.

[9]  J. Ioannidis,et al.  Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. , 2011, Circulation. Cardiovascular genetics.

[10]  M. Fukuda,et al.  Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  H. Lenz,et al.  Molecular predictive and prognostic markers in colon cancer. , 2010, Cancer treatment reviews.

[12]  Q. Pei,et al.  Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk , 2010, Clinical Cancer Research.

[13]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[14]  A. Carrato,et al.  UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy , 2010, British Journal of Cancer.

[15]  D. Sargent,et al.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.

[16]  Zhe-yi Hu,et al.  Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. , 2010, European journal of cancer.

[17]  M. Loriot,et al.  Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Sorbye,et al.  Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer , 2010, The Pharmacogenomics Journal.

[19]  F. Innocenti,et al.  Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Heinemann,et al.  UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. , 2009, World journal of gastroenterology.

[21]  B. Schackman,et al.  Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer , 2009, Cancer.

[22]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[23]  M. Adachi,et al.  The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. , 2009, Oncology research.

[24]  Hyo-jin Kim,et al.  Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. , 2009, Oncology reports.

[25]  T. Vos,et al.  Cost-Effectiveness of Interventions to Promote Physical Activity: A Modelling Study , 2009, PLoS medicine.

[26]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[27]  H. McLeod,et al.  UGT1A and irinotecan toxicity: keeping it in the family. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Crowley,et al.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Ioannidis,et al.  STrengthening the REporting of Genetic Association Studies (STREGA)— An Extension of the STROBE Statement , 2009, PLoS medicine.

[30]  P. Williamson,et al.  Methodological quality of pharmacogenetic studies: Issues of concern , 2008, Statistics in medicine.

[31]  J. Marshall,et al.  Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics , 2008, Cancer.

[32]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.

[33]  C. Punt,et al.  UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study , 2008, British Journal of Cancer.

[34]  J. Barrett,et al.  Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Mrhar,et al.  Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. , 2008, Pharmacogenomics.

[36]  Jin-Hwang Liu,et al.  UGT1A1*28 polymorphism predicts irinotecan‐induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma , 2008, Cancer.

[37]  Joseph G Ibrahim,et al.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.

[38]  M. Ratain,et al.  Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. , 2006, Pharmacogenomics.

[39]  Giuseppe Toffoli,et al.  The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Baiget,et al.  UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[42]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Rosell,et al.  Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism , 2003, Investigational New Drugs.

[44]  N McKoy,et al.  Systems to rate the strength of scientific evidence. , 2002, Evidence report/technology assessment.

[45]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[46]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[47]  M. S. Patel,et al.  An introduction to meta-analysis. , 1989, Health Policy.

[48]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[49]  S. Teutsch,et al.  Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? , 2009, Genetics in Medicine.

[50]  Linda A Bradley,et al.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review , 2009, Genetics in Medicine.

[51]  Amit X Garg,et al.  Systematic review and meta-analysis: when one study is just not enough. , 2008, Clinical journal of the American Society of Nephrology : CJASN.